

Under the Aegis of



Supported By



SAVE THE DATES

5th BCOS 2024

BEST CLINICAL ONCOLOGY SYMPOSIUM

Recent Clinical Updates
On
Lung Cancer, Breast Cancer, GI/GU
&
Other Malignancies

4TH & 5TH JULY, 2024

06:00PM - 09:00PM

PROGRAM CONVENER



DR. JB SHARMA

Senior Consultant and
Head of Department of Medical Oncology
Action Cancer Hospital, Delhi

CHAIRMAN SCIENTIFIC COMMITTEE



DR. NARESH SOMANI

MD, DM Director Oncology & HOD
Medical Oncology HCG Cancer Center,
Jaipur

REGISTER NOW



5th BCOS 2024

Date - 04th July 2024 - Day 1

TIME	TOPICS
06:00 - 06:05 PM	Welcome & Context Setting
	GU Cancer
06:05 - 06:15 PM	Characterization of Complete responders to Nivolumab + Gemcitabine - Cisplatin vs Gemcitabine - Cisplatin along and patients with lymph node - Only metastatic urothelial carcinoma from the Checkmate 901 trial
06:15 - 06:25 PM	Health related quality of life and pain in a phase 3 study of (177Lu)Lu-PSMA- 617 - Taxane - Naive -Patients with metastatic castration - resistant - prostate cancer (PSMAfore).
06:25 - 06:35 PM	Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
06:35 - 06:45 PM	A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.
06:45 0- 07:05 PM	Panel Discussion
07:05 - 07:15 PM	Quiz
5 mnts	Expert Comments
	Session : Breast Cancer
07:15 - 07:25 PM	DESTINY-Breast06: phase III study evaluating trastuzumab deruxtecan (T-DXd) compared with physician's choice of chemotherapy in patients with hormone receptor (HR)-positive/HER2-low or HER2-ultralow metastatic breast cancer (MBC) following previous endocrine therapy (Abstract LBA1000). T-DXd is approved in patients with HER2-low metastatic disease, which is more prevalent in HR-positive than HR-negative disease. This study is investigating the potential role of T-DXd even earlier in the course of treatment including in a cohort of patients with HER2-ultralow disease.

5th BCOS 2024

Date - 04th July 2024 - Day 1

TIME	TOPICS
07:25 - 07:35 PM	postMONARCH: phase III trial comparing fulvestrant plus abemaciclib vs fulvestrant alone for HR-positive/HER2-negative advanced disease following progression on previous CDK4/6 inhibitor plus endocrine therapy (Abstract LBA1001). Randomized phase II trials have shown inconsistent benefit of continuing a CDK4/6 inhibitor and switching endocrine therapy after progression on a CDK4/6 inhibitor. This is the first phase III trial to address this strategy.
07:35 - 07:45 PM	Quiz
07:45 - 07:50 PM	A-BRAVE: investigator-driven phase III study comparing adjuvant avelumab vs observation in patients with early-stage triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk of relapse following primary surgery and adjuvant chemotherapy (Abstract LBA500). Trials of immunotherapy in early-stage triple-negative breast cancer will help further define the treatment algorithm for these patients.
07:50 - 08:00 PM	NATALEE: a subgroup analysis of adjuvant ribociclib plus nonsteroidal aromatase inhibitors vs nonsteroidal aromatase inhibitors alone in patients with N0 HR-positive/HER2-negative early breast cancer (Abstract 512).
08:00 - 08:30 PM	Panel Discussion
08:30 - 08:40 PM	Quiz
08:40 - 08:45 PM	Expert Comments
08:45 - 09:05 PM	Pharma Session Sponsored 1
09:05 - 09:25 PM	Pharma Session Sponsored 2
09:25 - 09:30 PM	Closing Remarks

5th BCOS 2024

Date - 05th July 2024 - Day 2

TIME	TOPICS
06:00 - 06:05 PM	Welcome & Content Setting
	CNS
06:05 - 06:15 PM	Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
	GI Cancer 1 (Non-Colorectal)
06:15 - 06:25 PM	Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).
06:25 - 06:35 PM	Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW
	GI Cancer - 2 (Colorectal)
06:35 - 06:45 PM	Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.
	Gynaecological Cancer
06:45 - 06:50 PM	A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.
06:50 - 07:00 PM	Quiz
	Hemat (Myeloma)
07:00 - 07:10 PM	Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).

5th BCOS 2024

Date - 05th July 2024 - Day 2

TIME	TOPICS
	Hemat (Lymphoma)
07:10 - 07:20 PM	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
07:20 - 07:30 PM	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.
	Hemat (Leukemia)
07:30 - 07:40 PM	ASC4FIRST: primary results from the pivotal phase III study of asciminib vs investigator-selected tyrosine kinase (TKI) inhibitors, including imatinib and second-generation TKIs, in newly diagnosed patients with chronic myeloid leukemia (CML) (Abstract LBA6500). This is the first head-to-head trial comparing asciminib with all standards of care for patients with newly diagnosed CML. Asciminib has previously demonstrated statistically superior major molecular response rate and a favorable safety and tolerability profile compared with other TKIs in CML, and it has the potential to move into the frontline setting as a preferred TKI for newly diagnosed patients with CML.
07:40 - 07:45 PM	Quiz
	Lung Cancer
07:45 - 07:55 PM	LAURA: phase III trial of osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC (Abstract LBA4). The LAURA trial is among the most eagerly awaited NSCLC trials of ASCO 2024. If positive, this study may help us improve outcomes beyond the PACIFIC regimen or chemoradiation alone. Results of LAURA have the potential to change clinical practice by filling the last remaining gap where EGFR TKIs have not yet become a standard of care—unresectable stage III disease—and bringing a targeted approach with third-generation TKIs from stage IB to stage IV.

5th BCOS 2024

Date - 05th July 2024 - Day 2

TIME	TOPICS
08:05 - 08:15 PM	ADRIATIC: phase III trial investigating durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC) (Abstract LBA5). This important study may be the first in a very long time to bring progress to LS-SCLC potentially adding durvalumab to our armamentarium of curative options for patients with LS-SCLC. We have already seen improved outcomes with durvalumab and atezolizumab in patients with extensive-stage SCLC. ADRIATIC may expand the role of immunotherapy, in the early-stage setting similar to what has become our standard approach in non-small-cell lung cancer (NSCLC) (with the PACIFIC regimen). ADRIATIC has the potential to rapidly change clinical practice.
	Lung Cancer 2
08:15 - 08:25 PM	CROWN: 5-year progression-free survival and safety update of a phase III trial comparing lorlatinib with crizotinib for the treatment-naive patients with advanced ALK-positive NSCLC (Abstract LBA8503).
08:25 - 08:30 PM	Quiz
	Head & Neck Cancer
08:30 - 08:40 PM	A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
08:40 - 09:00 PM	Pharma Session Sponsored 1
09:00 - 09:20 PM	Pharma Session Sponsored 2
09:20 - 09:30 PM	Closing Remarks